A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease (NCT06958536)
A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR442970 in Adults With Moderate to Severe Crohn's Disease
🩺 Plain-English Summary (8th-Grade Level)
This is a phase 2b, randomized, double-blind, 3-arm study for the treatment of Crohn's disease. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Crohn's disease. The total study duration is up to 168 weeks, with a treatment period of up to 158 weeks including an open-label (OL) long-term extension (LTE) period of up to 104 weeks for eligible participants.
Who can join: Review the eligibility criteria below.
Location: Investigational Site Number: 8400024 — Tucson, Arizona
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (66 Sites)
Showing the first 25 of 66 sites.
- Investigational Site Number: 8400024 — Tucson, Arizona
- Investigational Site Number: 8400005 — Escondido, California
- Investigational Site Number: 8400001 — Lancaster, California
- Investigational Site Number: 8400017 — Kissimmee, Florida
- Investigational Site Number: 8400015 — Lighthouse PT, Florida
- Investigational Site Number 8400028 — Miami, Florida
- Investigational Site Number: 8400012 — Miami, Florida
- Investigational Site Number: 8400007 — Orlando, Florida
- Investigational Site Number: 8400011 — Palmetto Bay, Florida
- Investigational Site Number: 8400019 — Marietta, Georgia
- Investigational Site Number: 8400025 — Iowa City, Iowa
- Investigational Site Number: 8400006 — Kansas City, Kansas
- Investigational Site Number: 8400022 — Boston, Massachusetts
- Investigational Site Number: 8400008 — Wyoming, Michigan
- Investigational Site Number: 8400013 — St Louis, Missouri
- Investigational Site Number: 8400003 — Chapel Hill, North Carolina
- Investigational Site Number: 8400009 — Harrisburg, Pennsylvania
- Investigational Site Number: 8400002 — Fredericksburg, Texas
- Investigational Site Number: 8400016 — Ogden, Utah
- Investigational Site Number: 8400027 — Richmond, Virginia
- Investigational Site Number: 0360002 — Brisbane, Queensland
- Investigational Site Number: 0360004 — Kurralta Park, South Australia
- Investigational Site Number: 0360001 — Footscray,
- Investigational Site Number: 0560001 — Leuven,
- Investigative Site: 1560003 — Changsha,
📞 Contact the Study Coordinator
Phone: (800) 633-1610
Email: contact-us@sanofi.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Crohn's Disease
- A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD) — Birmingham, Alabama
- A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease — Birmingham, Alabama
- A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. — Sun City, Arizona
- Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice. — Blacktown, New South Wales
- Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients — San Francisco, California
- Dietary Therapy and Gut Microbiome in Crohn's Disease and Ulcerative Colitis — Boston, Massachusetts
Explore by condition: All Crohn's Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.